Insys Therapeutics (INSY) : Mondays money flow indicated an uptick to downtick ratio was at 1.81. The total value of inflow transactions on upticks was $1.1 million, whereas, the total value of outflow trades on downticks was $0.61 million. The total money flow was $0.49 million, which shows a mild bullish bias. The total money flow into the stock in block trades was $0.19 million. The total value of the trades done on upticks was $0.19 million. Insys Therapeutics (INSY) was trading with a -0.27% change over previous days close. It fell $0.05 during the day and reached $18.32. The stock was 3.97% compared to the previous weeks close.
Shares of INSYS Therapeutics, Inc. rose by 2.98% in the last five trading days and 22.16% for the last 4 weeks. INSYS Therapeutics, Inc. is up 40.55% in the last 3-month period. Year-to-Date the stock performance stands at -36.08%.
Insys Therapeutics (NASDAQ:INSY): The stock opened at $18.41 on Monday but the bulls could not build on the opening and the stock topped out at $18.50 for the day. The stock traded down to $18.21 during the day, due to lack of any buying support eventually closed down at $18.30 with a loss of -0.38% for the day. The stock had closed at $18.37 on the previous day. The total traded volume was 450,209 shares.
In a related news, The Securities and Exchange Commission has divulged that Fourteau Patrick, director of Insys Therapeutics, Inc., had unloaded 15,000 shares at an average price of $18.46 in a transaction dated on August 11, 2016. The total value of the transaction was worth $276,900.
Insys Therapeutics, Inc. is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company has two marketed products: Subsys, a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and Dronabinol SG Capsule, a generic equivalent to Marinol (dronabinol), an approved second-line treatment of chemotherapy-induced nausea and vomiting (CINV), and anorexia associated with weight loss in patients with AIDS. The Companys lead product candidate is Dronabinol oral solution, an orally administered liquid formulation of dronabinol. Dronabinol oral solution has demonstrated more rapidly detectable blood levels and a more reliable absorption profile than Marinol in its clinical studies.